<PAGE> 1
SCHEDULE 14A
(RULE 14A-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES
EXCHANGE ACT OF 1934 (AMENDMENT NO. )
FILED BY THE REGISTRANT [X] FILED BY A PARTY OTHER THAN THE REGISTRANT [ ]
- --------------------------------------------------------------------------------
Check the appropriate box:
[ ] Preliminary Proxy Statement
[X] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12
[ ] Confidential, For Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
ADVANCED MAGNETICS, INC.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
PAYMENT OF FILING FEE (CHECK THE APPROPRIATE BOX):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
1) Title of each class of securities to which transactions applies:
2) Aggregate number of securities to which transactions applies:
3) Per unit price or other underlying value of transaction computed pursuant
to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee
is calculated and state how it was determined):
4) Proposed maximum aggregate value of transaction:
5) Total fee paid:
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing and registration statement number,
or the form or schedule and the date of its filing.
1) Amount Previously Paid:
2) Form, Schedule or Registration Statement no.:
3) Filing Party:
4) Date Filed:
- --------------------------------------------------------------------------------
<PAGE> 2
ADVANCED MAGNETICS, INC.
61 MOONEY STREET
CAMBRIDGE, MASSACHUSETTS 02138
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON FEBRUARY 1, 2000
------------------------
The Annual Meeting of Stockholders ("Annual Meeting") of Advanced
Magnetics, Inc. (the "Company") will be held at the offices of the Company, 61
Mooney Street, Cambridge, Massachusetts 02138 on Tuesday, February 1, 2000 at
10:00 a.m., local time, to consider and act upon the following matters:
1. To elect six members of the Board of Directors to serve until the next
Annual Meeting and until their successors have been elected and
qualified; and
2. To transact such other business as may properly come before the meeting
or any adjournment thereof.
Stockholders of record at the close of business on December 7, 1999 are
entitled to notice of, and will be entitled to vote at, the Annual Meeting or
any adjournment thereof. A list of the stockholders of record entitled to vote
shall be available for inspection at the principal office of the Company for ten
days prior to the Annual Meeting. The stock transfer books of the Company will
remain open between the record date and the date of the Annual Meeting.
By Order of the Board of Directors
MARLENE KAPLAN GOLDSTEIN,
Secretary
Cambridge, Massachusetts
December 17, 1999
WHETHER OR NOT YOU EXPECT TO ATTEND THE MEETING, PLEASE COMPLETE, DATE AND
SIGN THE ENCLOSED PROXY AND MAIL IT PROMPTLY IN THE ENCLOSED ENVELOPE IN ORDER
TO ASSURE REPRESENTATION OF YOUR SHARES. NO POSTAGE NEED BE AFFIXED IF THE PROXY
IS MAILED IN THE UNITED STATES.
<PAGE> 3
ADVANCED MAGNETICS, INC.
61 MOONEY STREET
CAMBRIDGE, MASSACHUSETTS 02138
PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON FEBRUARY 1, 2000
This proxy statement is furnished in connection with the solicitation of
proxies by the Board of Directors of Advanced Magnetics, Inc. (the "Company")
for use at the Annual Meeting of Stockholders ("Annual Meeting") to be held at
the offices of the Company at 61 Mooney Street, Cambridge, Massachusetts 02138,
on Tuesday, February 1, 2000 at 10:00 a.m., local time and at any adjournment of
the Annual Meeting.
December 7, 1999 was the record date for the determination of stockholders
entitled to vote at the Annual Meeting. On that date, there were 6,752,027
shares of common stock, $.01 par value per share, of the Company (the "Common
Stock") outstanding. Each stockholder is entitled to one vote for each share of
Common Stock held by such stockholder on the record date.
At the Annual Meeting, a proposal to elect Messrs. Leonard Baum, Jerome
Goldstein, Joseph Lassiter III, Michael Loberg, Edward Roberts and George
Whitesides as directors will be subject to a vote of stockholders. Where a
choice has been specified on the accompanying proxy card with respect to this
proposal, the shares represented by the proxy will be voted in accordance with
the specifications, and will be voted in favor of the proposal if no
specification is indicated.
The Board of Directors of the Company knows of no other matters to be
presented at the Annual Meeting. If any other matter should be presented at the
Annual Meeting upon which a vote properly may be taken, shares represented by
all proxies received by the Board of Directors will be voted with respect
thereto in accordance with the judgment of the persons named in the proxies. Any
proxy may be revoked by a stockholder at any time before its exercise by
delivery of written revocation to the Secretary of the Company.
The Company's Annual Report, including audited financial statements for the
fiscal year ended September 30, 1999, is being mailed to the stockholders
entitled to vote at the Annual Meeting along with the mailing of this proxy
statement. This proxy statement and accompanying form of proxy will first be
mailed to stockholders on or about December 28, 1999.
VOTING PROCEDURES
The representation in person or by proxy of at least a majority of the
outstanding shares of Common Stock entitled to vote at the Annual Meeting is
necessary to constitute a quorum for the transaction of business. Votes withheld
from any nominee, abstentions and broker "non-votes" are counted as present or
represented for purposes of determining the presence or absence of a quorum for
the meeting. A "non-vote" occurs when a nominee holding shares for a beneficial
owner votes on one proposal, but does not vote on another proposal because, with
respect to such other proposal, the nominee does not have discretionary voting
power and has not received instructions from the beneficial owner. Votes will be
tabulated by American Stock Transfer and Trust Company as Transfer
Agent/Registrar of the Company.
Directors are elected by a plurality of the votes cast by stockholders
entitled to vote at the meeting. The affirmative vote of the holders of a
majority of the shares of Common Stock present or represented, and voting, at
the Annual Meeting is required for approval of all other matters, if any, to be
submitted to stockholders at the meeting. Abstentions and broker "non-votes" are
not considered to have been voted on any matter and have the practical effect of
reducing the number of affirmative votes required to achieve a majority for such
matter.
A large number of banks and brokerage firms are participating in the ADP
Investor Communication Services online program. This program provides eligible
stockholders the opportunity to vote via the Internet or by telephone. If your
bank or brokerage firm is participating in ADP's program, your voting form will
provide instructions. If your voting form does not reference Internet or
telephone information, please complete and return the paper proxy card in the
self-addressed, postage paid envelope provided.
<PAGE> 4
DEADLINE FOR SUBMISSION OF STOCKHOLDER PROPOSALS
Proposals of stockholders intended for inclusion in the proxy statement to
be furnished to all stockholders entitled to vote at the next annual meeting of
stockholders of the Company must be received at the Company's principal
executive offices not later than August 30, 2000. The deadline for providing
timely notice to the Company of matters that stockholders otherwise desire to
introduce at the next annual meeting of stockholders of the Company is November
13, 2000. The Company may exercise its discretionary voting authority to direct
the voting of proxies on any matter submitted for a vote at the annual meeting
of stockholders if notice concerning proposal of such matter was not received
prior to November 13, 2000. In order to curtail any controversy as to the date
on which a proposal was received by the Company, it is suggested that proponents
submit their proposals by Certified Mail, Return Receipt Requested.
PRINCIPAL HOLDERS OF VOTING SECURITIES
The following table sets forth certain information, as of December 7, 1999,
with respect to the beneficial ownership of the Company's Common Stock by (i)
each person known by the Company to own beneficially more than 5% of the
outstanding shares of Common Stock, (ii) the directors, (iii) the chief
executive officer and each of the four other most highly compensated executive
officers of the Company as of September 30, 1999 whose annual compensation
exceeded $100,000 (the "Named Officers") and (iv) all directors and executive
officers of the Company as a group:
<TABLE>
<CAPTION>
NUMBER OF PERCENTAGE OF
SHARES COMMON
NAME AND ADDRESS BENEFICIALLY STOCK
OF BENEFICIAL OWNER(1) OWNED OUTSTANDING
---------------------- ------------ -------------
<S> <C> <C>
BVF Partners L.P.(2)................................ 919,235 13.6%
227 West Monroe Street, Suite 1600
Chicago, Illinois 60606
Jerome Goldstein(3)(4)(5)........................... 696,547 10.3%
Marlene Kaplan Goldstein(3)(4)...................... 681,437 10.1%
Dimensional Fund Advisors, Inc.(6).................. 431,450 6.4%
1299 Ocean Avenue, 11th Floor
Santa Monica, CA 90401
Eiken Chemical Co., Ltd............................. 375,000 5.6%
1-33-8 Hongo
Bunkyo-Ku
Tokyo, Japan
Edward B. Roberts, Ph.D.(7)......................... 103,181 1.5%
George M. Whitesides, Ph.D.(8)...................... 88,250 1.3%
Mark C. Roessel(9).................................. 21,948 *
Leonard M. Baum(10)................................. 17,711 *
Joseph B. Lassiter III, Ph.D.(11)................... 16,000 *
Michael D. Loberg, Ph.D.(12)........................ 16,000 *
Jerome M. Lewis, Ph.D.(13).......................... 11,982 *
Paula M. Jacobs, Ph.D.(14).......................... 11,975 *
All directors and executive officers as a group
(13 persons)(15).................................. 1,009,957 14.6%
</TABLE>
- ---------------
* Less than 1%.
(1) Unless otherwise indicated, each stockholder referred to above has sole
voting and investment power with respect to the shares listed and the
address of each stockholder is: c/o Advanced Magnetics, Inc., 61 Mooney
Street, Cambridge, Massachusetts 02138.
2
<PAGE> 5
(2) Based upon a Form 4 for the month of October 1999, filed with the
Securities and Exchange Commission, a copy of which was provided to the
Company pursuant to SEC rules, BVF Partners L.P. ("Partners") and BVF,
Inc., an investment advisor to and general partner of Partners, are the
beneficial owners of 919,235 shares. Mark N. Lampert is the sole
shareholder of and sole director of BVF, Inc. Partners is the general
partner of Biotechnology Value Fund, L.P.
(3) Jerome Goldstein and Marlene Kaplan Goldstein are husband and wife, and
each disclaims control or beneficial ownership of shares held by the other.
(4) Includes 51,900 shares held by the Kaplan Goldstein Family Foundation, a
charitable foundation whose trustees are Jerome Goldstein, Marlene Kaplan
Goldstein and their two adult children.
(5) Includes 20,625 shares issuable to Jerome Goldstein pursuant to options
exercisable on or before February 5, 2000.
(6) Based upon a Schedule 13G filed with the Securities and Exchange Commission
on February 10, 1999, Dimensional Fund Advisors Inc. ("Dimensional"), an
investment advisor registered under the Investment Advisor's Act of 1940,
is deemed to have beneficial ownership of 431,450 shares as of December 31,
1998, all of which shares are held by investment companies to which it
furnishes investment advice and certain other investment vehicles for which
it serves as investment manager. Dimensional disclaims beneficial ownership
of all such shares.
(7) Includes 30,500 shares held by Dr. Roberts as trustee for his children and
20,750 shares issuable to Dr. Roberts pursuant to options exercisable on or
before February 5, 2000.
(8) Includes 20,750 shares issuable to Dr. Whitesides pursuant to options
exercisable on or before February 5, 2000.
(9) Includes 9,291 shares owned as joint tenant with right of survivorship with
Mr. Roessel's spouse and 9,700 shares issuable to Mr. Roessel under options
exercisable on or before February 5, 2000.
(10) Includes 15,000 shares issuable to Mr. Baum pursuant to options exercisable
on or before February 5, 2000.
(11) Represents 16,000 shares issuable to Dr. Lassiter pursuant to options
exercisable on or before February 5, 2000.
(12) Represents 16,000 shares issuable to Dr. Loberg pursuant to options
exercisable on or before February 5, 2000.
(13) Includes 10,375 shares issuable to Dr. Lewis pursuant to options
exercisable on or before February 5, 2000.
(14) Includes 980 shares held by Dr. Jacobs' spouse as custodian for the benefit
of her daughter and 9,500 shares issuable to Dr. Jacobs pursuant to options
exercisable on or before February 5, 2000.
(15) Includes 83,830 shares held in family or charitable trusts and custodial
accounts for various directors' and officers' children, 9,291 shares owned
jointly with spouses of directors and officers and 160,850 shares issuable
under options exercisable on or before February 5, 2000.
ELECTION OF DIRECTORS
The persons named in the enclosed proxy will vote to elect as directors the
six nominees named below, all of whom are now directors of the Company, unless
authority to vote for the election of any or all of the directors is withheld by
marking the proxy to that effect.
Each director will be elected to hold office until the next annual meeting
of stockholders and until his successor is elected and qualified, or until his
earlier death, resignation or removal. Each of the nominees has indicated his
willingness to serve, if elected, but if a nominee should be unable to serve,
the proxies may be voted for a substitute nominee designated by management.
3
<PAGE> 6
Leslie Goldstein, who served as a director of the Company since 1981,
resigned during the year for personal reasons. The Company expresses its thanks
to Mr. Goldstein for his years of service on the Board of Directors.
Set forth below are the name and age of each nominee and the positions and
offices held by him, his principal occupation and business experience during the
past five years and the year of the commencement of his term as a director of
the Company.
Leonard M. Baum, age 46, has been a director since 1997. He has been
President and Chief Operating Officer of the Company since June 1997 and was a
Senior Vice President of the Company from September 1994 to September 1997. He
was formerly employed by Squibb Diagnostics from March 1986 to September 1994,
most recently as Senior Director, Worldwide Regulatory Affairs.
Jerome Goldstein, age 60, has been a director since 1981. He is a founder
of the Company and has been Chairman of the Board of Directors, Chief Executive
Officer and Treasurer since the Company's organization in November 1981. Mr.
Goldstein was President of the Company from the Company's organization in
November 1981 until June 1997.
Joseph B. Lassiter III, Ph.D., age 52, has been a director since 1997. He
has been a Lecturer and Professor at the Harvard Business School since September
1996. He was the President of Wildfire Communications, Inc., a
telecommunications software company, from July 1994 to February 1996, and was
Vice President at Teradyne, Inc., a manufacturer of automatic test equipment,
from January 1977 to February 1994. He is a director of RSA Security, Inc.
Michael D. Loberg, Ph.D., age 52, has been a director since 1997. He has
been Chief Executive Officer of NitroMed, Inc. since September 1997. Prior to
that, he served for twenty years in various senior management positions at
Bristol-Myers Squibb, including President of Squibb Diagnostics, President of
BMS Northern Europe and President of BMS Specialty Pharmaceuticals.
Edward B. Roberts, Ph.D., age 64, has been a director since 1982. He has
been Professor at the Sloan School at the Massachusetts Institute of Technology
since 1961. He was a co-founder and the Chairman of Pugh-Roberts Associates,
Inc., a management consulting firm that is now a division of PA Consulting
Group, Inc. He is also a general partner of Zero Stage Capital Management, L.P.,
a venture capital limited partnership. He is also a director of SelfCare, Inc.,
PegaSystems, Inc., Medical Information Technology Inc. and NETsilicon, Inc.
George M. Whitesides, Ph.D., age 60, has been a director since 1981. He has
been a Professor of Chemistry at Harvard University since July 1982. He is a
director of Dexter Corporation, a manufacturer of specialty material product,
Geltex Inc., a biopharmaceutical company and Life Technologies, Inc., a supplier
of products used in life sciences research and the commercial manufacture of
genetically engineered products.
BOARD AND COMMITTEE MEETINGS
The Board of Directors met three times during the fiscal year ended
September 30, 1999. Each director attended at least 75% of the meetings of the
Board of Directors and all the Committees on which he served with the exception
of Joseph B. Lassiter III and George M. Whitesides, each of whom attended two
meetings.
Jerome Goldstein, Joseph B. Lassiter III, and Edward B. Roberts serve as
members of the Audit Committee of the Board of Directors. The Audit Committee
oversees generally the financial controls and practices of the Company. The
Audit Committee conducted one formal meeting apart from Board of Directors
meetings during the fiscal year ended September 30, 1999.
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Exchange Act requires the Company's directors,
executive officers and holders of more than 10% of the Company's Common Stock
(collectively, "Reporting Persons") to file with the Commission initial reports
of ownership and reports of changes in ownership of Common Stock of the Company.
Such persons are required by regulations of the Commission to furnish the
Company with copies of
4
<PAGE> 7
all such filings. Based on its review of the copies of such filings received by
it with respect to the fiscal year ended September 30, 1999, and written
representations from certain of its directors and executive officers, the
Company believes that all Reporting Persons complied with all Section 16(a)
filing requirements in the fiscal year ended September 30, 1999 with the
following exceptions: George M. Whitesides, director of the Company, failed to
file on a timely basis one report relating to one transaction (an exercise of a
stock option) and Leslie Goldstein, former director of the Company, failed to
file a report relating to the grant by the Company of an option to him, which
option subsequently terminated prior to exercise after his resignation.
COMPENSATION AND OTHER INFORMATION
CONCERNING DIRECTORS AND OFFICERS
EXECUTIVE COMPENSATION SUMMARY
The following table sets forth the annual and long-term compensation of
each of the Named Officers for each of the fiscal years ended September 30,
1999, 1998 and 1997:
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
LONG-TERM COMPENSATION
AWARDS(2)
ANNUAL ---------------------------------
COMPENSATION(1) SECURITIES
----------------- UNDERLYING ALL OTHER
NAME AND PRINCIPAL POSITION YEAR SALARY($) OPTIONS/SARS(#) COMPENSATION($)
--------------------------- ---- --------- --------------- ---------------
<S> <C> <C> <C> <C>
Jerome Goldstein............................ 1999 243,001 20,000 19,900(3)
Chairman of the Board of Directors, 1998 235,273 0 18,100(3)
Chief Executive Officer and Treasurer 1997 228,115 30,000 16,800(3)
Leonard M. Baum............................. 1999 212,759 10,000 2,000(4)
President and Chief Operating Officer 1998 204,632 10,000 2,000(4)
1997 194,104 20,000 2,000(4)
Paula M. Jacobs, Ph.D....................... 1999 131,073 5,000 2,000(4)
Vice President -- Development 1998 126,592 0 2,000(4)
1997 122,861 9,000 2,000(4)
Jerome M. Lewis, Ph.D....................... 1999 126,471 5,000 2,000(4)
Vice President -- Scientific Operations 1998 121,209 0 2,000(4)
1997 116,413 8,000 2,000(4)
Mark C. Roessel............................. 1999 121,011 5,000 2,000(4)
Vice President -- Regulatory Affairs 1998 112,337 0 2,000(4)
1997 103,519 9,000 2,000(4)
</TABLE>
- ---------------
(1) Excludes perquisites and other personal benefits, the aggregate annual
amount of which for each officer was less than the lesser of $50,000 or 10%
of the total salary and bonus reported.
(2) The Company did not grant any restricted stock awards or stock appreciation
rights or make any long term incentive plan payouts during the fiscal years
ended September 30, 1999, 1998 and 1997.
(3) Includes $17,900, $16,100 and $14,800 in premiums on a term life insurance
policy related to coverage in the fiscal years ended September 30, 1999,
1998 and 1997, respectively, in the event of the death of Mr. Goldstein and
his wife to a trust for the benefit of their children and $2,000 in
contributions for Mr. Goldstein's benefit to the Company's 401(k) plan.
(4) Represents amount contributed for the benefit of the Named Officer to the
Company's 401(k) plan.
5
<PAGE> 8
OPTION GRANTS IN THE LAST FISCAL YEAR
The following table sets forth grants to the Named Officers of stock
options during the fiscal year ended September 30, 1999:
OPTION/SAR GRANTS IN LAST FISCAL YEAR(1)
<TABLE>
<CAPTION>
INDIVIDUAL GRANTS
-----------------------------------------------------
PERCENT OF
TOTAL POTENTIAL REALIZABLE
NUMBER OF OPTIONS/ VALUE AT ASSUMED
SECURITIES SARS ANNUAL RATES OF
UNDERLYING GRANTED STOCK PRICE
OPTION/ TO APPRECIATION FOR
SARS EMPLOYEES EXERCISE OF OPTION TERM(2)
GRANTED IN FISCAL BASE PRICE EXPIRATION --------------------
NAME (#) YEAR ($/SH) DATE 5%($) 10%($)
---- ---------- ---------- ----------- ---------- -------- --------
<S> <C> <C> <C> <C> <C> <C>
Jerome Goldstein............ 20,000(3) 16.8 4.40 5/4/04 22,103 48,841
Leonard M. Baum............. 10,000(4) 8.4 4.00 5/4/09 25,156 63,750
Paula M. Jacobs, Ph.D....... 5,000(4) 4.2 4.00 5/4/09 12,578 31,875
Jerome M. Lewis, Ph.D....... 5,000(4) 4.2 4.00 5/4/09 12,578 31,875
Mark C. Roessel............. 5,000(4) 4.2 4.00 5/4/09 12,578 31,875
</TABLE>
- ---------------
(1) No stock appreciation rights ("SARs") were granted in the fiscal year ended
September 30, 1999.
(2) Amounts reported in these columns represent amounts that may be realized
upon exercise of the options immediately prior to the expiration of their
term assuming the specified compounded rates of appreciation (5% and 10%) on
the Company's Common Stock over the term of the options. These numbers are
calculated based on rules promulgated by the Securities and Exchange
Commission and do not reflect the Company's estimate of future stock price
growth. Actual gains, if any, on stock option exercises and Common Stock
holdings are dependent on the timing of such exercise and the future
performance of the Company's Common Stock. There can be no assurance that
the rates of appreciation assumed in this table can be achieved or that the
amounts reflected will be received by the individuals.
(3) Options granted under the Company's 1993 Stock Plan at an exercise price
equal to 110% of the fair market value of the Company's Common Stock on the
date of grant. The options have a term of five years from the date of grant
and become exercisable as to 25% of the shares on each of the first four
anniversaries of the date of grant until such options are fully exercisable.
(4) Options granted under the Company's 1993 Stock Plan at an exercise price
equal to the fair market value of the Company's Common Stock on the date of
grant. The options have a term of ten years from the date of grant and
become exercisable as to 25% of the shares on each of the first four
anniversaries of the date of grant until such options are fully exercisable.
6
<PAGE> 9
OPTION EXERCISES AND FISCAL YEAR-END VALUES
The following table sets forth information as to the Named Officers with
respect to options to purchase the Company's Common Stock held by each Named
Officer, including (i) the number of shares of Common Stock purchased upon
exercise of options in fiscal 1999, (ii) the net value realized upon such
exercise, (iii) the number of unexercised options outstanding at September 30,
1999 and (iv) the value of such unexercised options at September 30, 1999:
AGGREGATED OPTION/SAR EXERCISES IN LAST FISCAL YEAR AND
SEPTEMBER 30, 1999 OPTION VALUES
<TABLE>
<CAPTION>
NUMBER OF VALUE OF UNEXERCISED
SECURITIES UNDERLYING IN-THE-MONEY
UNEXERCISED OPTIONS/SARS AT OPTIONS/SARS AT
SHARES VALUE SEPTEMBER 30, 1999 (#) SEPTEMBER 30, 1999 ($)(2)
ACQUIRED ON REALIZED ----------------------------- ---------------------------
NAME EXERCISE(#) ($)(1) EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
---- ----------- -------- ------------- ------------- ----------- -------------
<S> <C> <C> <C> <C> <C> <C>
Jerome Goldstein............. -- -- 20,625 29,375 -- --
Leonard M. Baum.............. -- -- 15,000 25,000 -- --
Paula M. Jacobs, Ph.D........ 820 1,879 9,500 8,000 -- --
Jerome M. Lewis, Ph.D........ 509 1,167 10,375 7,625 -- --
Mark C. Roessel.............. -- -- 9,700 8,500 -- --
</TABLE>
- ---------------
(1) Amounts disclosed in this column do not reflect amounts actually received
by the Named Officers but are calculated based on the difference between
the fair market value of the Company's Common Stock on the date of exercise
and the exercise price of the options. The Named Officers will receive cash
only if and when they sell the Common Stock issued upon exercise of the
options, and the amount of cash received by such individuals is dependent
on the price of the Company's Common Stock at the time of such sale.
(2) Value is based on the difference between the option exercise price and the
fair market value at September 30, 1999 ($3.125 per share as quoted on the
American Stock Exchange) multiplied by the number of shares underlying the
option. All options held by the Named Officers have an exercise price of
greater than $3.125 per share, and, therefore, no such options are
"in-the-money."
7
<PAGE> 10
REPORT ON EXECUTIVE COMPENSATION BY THE BOARD OF DIRECTORS
To Our Stockholders:
The Board of Directors of the Company is responsible for establishing and
administering the Company's executive compensation programs. The Company's
executive compensation policies rely on regular cash salaries and significant
equity incentives in the form of stock options.
Salaries of the five highest paid executives are listed on the Executive
Compensation Summary table found on page 5. On an annual basis, the Board
reviews these salaries and, while it is not required to, it may in its
discretion increase the salaries. The Board has typically adjusted the
compensation of each of the executives by the same percentage amount. The amount
of the annual increases has historically reflected the Board's subjective
assessment of the salary level necessary for the Company to remain at the
approximate median in compensation levels when compared to other
biopharmaceutical companies of comparable size and geographical location (which
together comprise a subset of the Company's Peer Group Index referred to in the
Performance Graph below), and the Board's subjective judgment as to Company
performance. In fiscal 1999, the Board determined the Company's performance
primarily by reference to the progress of the Company's clinical trials and
product development efforts. The Board determined to grant the Named Officers
the compensation disclosed in the Executive Compensation Summary table found on
page 5.
In order to align the interests of executives and other employees with
stockholders and motivate them to work for the long-term growth of the Company,
the Company provides significant stock option grants to its employees.
Executives are typically considered every two years for stock option grants, and
it is the Company's policy to weight total compensation heavily toward equity
compensation through stock options. Options are generally granted at fair market
value and become exercisable ratably over a four-year period. The actual number
of stock options granted to executives is not determined pursuant to any
formula, but rather they are awarded subjectively by the Board in its
discretion.
COMPANY PERFORMANCE AND CEO COMPENSATION
The compensation of the Chief Executive Officer has typically been adjusted
annually by the same percentage as the average percentage increase for all of
the Company's employees. In exercising its discretion, the Board takes into
consideration, among other things, the Company's progress in achieving the goals
of the Board of Directors (focusing in recent periods on the Company's product
development and clinical trial progress), and the compensation packages of
executive officers of comparable companies of similar size in the
biopharmaceutical industry.
As a result of the Company's performance and his individual contribution,
Jerome Goldstein was awarded the amounts reflected in the Executive Compensation
Summary table on page 5 in fiscal 1999.
Members of the Board of Directors:
Leonard M. Baum Michael D. Loberg
Jerome Goldstein Edward B. Roberts
Joseph B. Lassiter III George M. Whitesides
COMPENSATION OF DIRECTORS
During the fiscal year ended September 30, 1999, directors received no cash
compensation for their services as directors, except for reimbursement of
expenses incurred in connection with attending meetings.
Under the terms of the Company's 1992 Director Plan, each person who was a
member of the Company's Board of Directors on November 5, 1991 (or was appointed
to the Board of Directors thereafter), and who was not an employee or an officer
of the Company, was automatically granted on November 5, 1991 (or the date of
their appointment to the Board of Directors, if thereafter) (the "1992 Initial
Grant Date") and November 5, 1996 an option to purchase 5,000 shares of the
Company's Common Stock, and will receive an option to purchase an additional
5,000 shares on each successive fifth anniversary of the 1992 Initial Grant Date
if he or
8
<PAGE> 11
she is then a member of the Board of Directors. The exercise price of options
granted under the 1992 Director Plan is the fair market value of the Company's
Common Stock on the date the option is granted (subject to adjustment for any
dividend, stock split or other relevant change in the Company's capitalization).
Each option granted under the 1992 Director Plan first becomes exercisable with
respect to 20% of the shares subject to such option on the day preceding each
annual anniversary of the date of grant, until the option is exercisable with
respect to all of the shares subject thereto.
Under the terms of the Company's 1993 Director Plan, each person who was a
member of the Company's Board of Directors on November 10, 1992 (or was
appointed to the Board of Directors thereafter), and who was not an employee or
an officer of the Company, was automatically granted on November 10, 1992 (or
the date of their appointment to the Board of Directors, if thereafter) (the
"1993 Initial Grant Date") and November 10, 1998 an option to purchase 5,000
shares of the Company's Common Stock, and will receive an option to purchase an
additional 5,000 shares on each successive sixth anniversary of the 1993 Initial
Grant Date if he or she is then a member of the Board of Directors. The exercise
price of options granted under the 1993 Director Plan is the fair market value
of the Company's Common Stock on the date the option is granted (subject to
adjustment for any dividend, stock split or other relevant change in the
Company's capitalization). Each option granted under the 1993 Director Plan
first becomes exercisable with respect to 20% of the shares subject to such
option on the day preceding each annual anniversary of the date of grant, until
the option is exercisable with respect to all of the shares subject thereto.
Directors are also eligible for option grants under the terms of the
Company's 1993 Stock Plan. On November 10, 1999, each of the Company's
non-employee directors was granted an option under the Company's 1993 Stock Plan
to purchase 10,000 shares of the Company's Common Stock at $3.50 per share, the
closing price of the Company's Common Stock as quoted on the American Stock
Exchange for that day. Each of these options was exercisable in full on the date
of its grant.
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
The Company does not have a Compensation Committee. The Board of Directors
was responsible for determining compensation of executive officers of the
Company. During the fiscal year ended September 30, 1999, Jerome Goldstein, the
Company's Chairman of the Board of Directors, Chief Executive Officer and
Treasurer, and Leonard Baum, the Company's Chief Operating Officer and
President, participated in the establishment and administration of the Company's
executive compensation programs. Mr. Goldstein and Mr. Baum abstained from
voting with respect to decisions concerning their respective compensation as
executive officers of the Company.
9
<PAGE> 12
STOCK PERFORMANCE GRAPH
The following graph compares the yearly percentage change in the cumulative
total stockholder return on the Company's Common Stock during the five fiscal
years ended September 30, 1999 with the cumulative total return on the American
Stock Exchange Market Value Index and the Company's Peer Group based on SIC Code
2834 (pharmaceutical preparations). The comparisons assume $100 was invested on
October 1, 1994 in the Company's Common Stock in the American Stock Exchange
Market Value Index and with the Company's Peer Group and assumes reinvestment of
dividends, if any.
<TABLE>
<CAPTION>
ADVANCED MAGNETICS, INC. AMEX MARKET INDEX SIC CODE 2834
------------------------ ----------------- -------------
<S> <C> <C> <C>
1994 100.00 100.00 100.00
1995 157.25 120.49 144.56
1996 101.53 125.40 191.80
1997 65.27 152.50 272.51
1998 45.80 133.20 361.34
1999 19.08 155.13 370.31
</TABLE>
The stock price performance shown on the graph is not necessarily
indicative of future price performance. Information used in the graph was
obtained from Media General Financial Services, a source the Company believes is
reliable. However, the Company is not responsible for any errors or omissions in
such information.
10
<PAGE> 13
INDEPENDENT PUBLIC ACCOUNTANTS
The Board of Directors has selected the firm of PricewaterhouseCoopers LLP,
as the Company's independent accountants for the 2000 fiscal year.
PricewaterhouseCoopers LLP has served as the Company's independent accountants
since the Company's inception. Representatives of PricewaterhouseCoopers LLP are
expected to be present at the Annual Meeting. They will have the opportunity to
make a statement if they desire to do so and will also be available to respond
to appropriate questions from stockholders.
EXPENSES AND SOLICITATION
All costs of solicitation of proxies will be borne by the Company. In
addition, the Company has retained Corporate Investor Communications, Inc.
("CIC") to act as a proxy solicitor in connection with the Annual Meeting. The
Company has agreed to pay approximately $10,000, plus reasonable out of pocket
expenses, to CIC for proxy solicitation services. In addition to solicitations
by mail, the Company's directors, officers and regular employees, without
additional remuneration, may solicit proxies by telephone, telegraph and
personal interviews. Brokers, custodians and fiduciaries will be requested to
forward proxy soliciting material to the owners of stock held in their names,
and the Company will reimburse them for their out-of-pocket expenses in this
connection.
By Order of the Board of Directors
MARLENE KAPLAN GOLDSTEIN,
Secretary
THE BOARD OF DIRECTORS WELCOMES STOCKHOLDERS WHO WISH TO ATTEND THE
MEETING. WHETHER OR NOT YOU PLAN TO ATTEND, YOU ARE URGED TO COMPLETE, DATE,
SIGN AND RETURN THE ENCLOSED PROXY IN THE ACCOMPANYING ENVELOPE. A PROMPT
RESPONSE WILL GREATLY FACILITATE ARRANGEMENTS FOR THE MEETING AND YOUR
COOPERATION WILL BE APPRECIATED. STOCKHOLDERS WHO ATTEND THE MEETING MAY VOTE
THEIR STOCK PERSONALLY EVEN THOUGH THEY HAVE SENT IN THEIR PROXIES BY PROVIDING
WRITTEN NOTICE TO THE SECRETARY OF THE COMPANY REVOKING THEIR PRIOR PROXY.
11
<PAGE> 14
ADVANCED MAGNETICS, INC.
PROXY FOR THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD FEBRUARY 1, 2000
PROXY SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
PROXY
The undersigned, revoking all prior proxies, hereby appoint(s) Jerome
Goldstein and Edward B. Roberts, and each of them, with full power of
substitution, as proxies to represent and vote as designated herein, all shares
of stock of Advanced Magnetics, Inc. (the "Company") which the undersigned would
be entitled to vote if personally present at the Annual Meeting of Stockholders
of the Company to be held at the offices of the Company, 61 Mooney Street,
Cambridge, Massachusetts 02138, on Tuesday, February 1, 2000 at 10:00 a.m.,
local time, and at any adjournment thereof.
IN THEIR DISCRETION, THE PROXIES ARE AUTHORIZED TO VOTE UPON SUCH OTHER
MATTERS AS PROPERLY MAY COME BEFORE THE MEETING OR ANY ADJOURNMENT THEREOF.
This proxy, when properly executed, will be voted in the manner directed
herein by the undersigned stockholder(s). IF NO DIRECTION IS GIVEN, THIS PROXY
WILL BE VOTED FOR THE ELECTION OF DIRECTORS, AND AUTHORITY WILL BE DEEMED
GRANTED UNDER ITEM 2. Attendance of the undersigned at the meeting or at any
adjournment thereof will not be deemed to revoke this proxy unless the
undersigned shall revoke this proxy in writing.
-----------
CONTINUED AND TO BE SIGNED ON REVERSE SIDE SEE REVERSE
SIDE
-----------
/X/ PLEASE MARK
VOTES AS IN
THIS EXAMPLE
1. To Elect Directors.
NOMINEES: Leonard M. Baum, Jerome Goldstein, Joseph B. Lassiter III, Michael D.
Loberg, Edward B. Roberts and George M. Whitesides
FOR WITHHELD*
/ / / /
_______________________________
*To withhold your vote for any individual nominee, write the nominee's name in
the space provided above.
2. To transact such other business as may properly come before the Annual
Meeting.
MARK HERE MARK HERE IF
FOR ADDRESS / / YOU PLAN TO / /
CHANGE AND ATTEND THE
NOTE AT LEFT MEETING
Sign as name appears. Joint owners must both sign. Attorney, executor,
administrator, trustee or guardian must give title. A corporation or partnership
must sign its name by authorized person.
Signature:________________________________Date:________________
Signature:________________________________Date:________________
